Different case series have reported clinically significant responses in pretreated NEC patients harboring BRAF V600E mutations with BRAF/MEK targeted agents, even though no specific information about UPO-NENs has been reported so far to our knowledge [122,123,124]. The gene discussed is BRAF; the disease is neuroendocrine carcinoma.